CVRx Q3 revenue up 70% to $10.5M, raises FY2023 revenue guidance

CVRx, Inc.

2023-Q3 EPS reported -$1.55 revenue$27,990,000

Revenue $10.5M (+70% YoY); U.S. HF revenue $9.4M (+92% YoY).
Net loss $9.0M ($0.43/sh) vs $9.8M ($0.48/sh) in Q3 2022; cash burn improved to $8.2M from $13.0M in Q2.
Active implanting centers 159 (+75% YoY); sales territories grew to 35.
FY2023 revenue guidance raised to $38.5M-$39.0M (from $37.0M-$38.5M); Q4 revenue expected $10.5M-$11.0M.
CMS advisory panel unanimously recommended higher Barostim payment code; final rule expected late Nov.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

CVRx, Inc. reported the third quarter of 2023 results: revenue $10.5 million, net income $9.0 million, EPS $0.43 per share.

Period: the third quarter of 2023
Revenue: $10.5 million
Net income: $9.0 million
EPS: $0.43 per share
Result: reported results

Exact text from the filing

cardiovascular diseases, today announced its financial and operating results for the third quarter of 2023. Recent Highlights · Total revenue for the third quarter of 2023 was $10.5 million, an increase of 70% over the prior year quarter · U.S. Heart Failure (HF) revenue for the third quarter of 2023 was $9.4 million, an increase of 92% over the prior year quarter ·

View on SEC.gov

53 earnings releases filed in the last 30 days. Browse all earnings releases →

CVRx, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-111750

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.